Caribou Biosciences Inc. (CRBU)
1.58
0.02 (1.28%)
At close: Jan 15, 2025, 9:55 AM
undefined% (undefined)
| Bid | 1.58 |
| Market Cap | 143.53M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.66 |
| PE Ratio (ttm) | -0.95 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.59 |
| Volume | 414,725 |
| Avg. Volume (20D) | 1,560,495 |
| Open | 1.61 |
| Previous Close | 1.56 |
| Day's Range | 1.58 - 1.69 |
| 52-Week Range | 1.50 - 8.33 |
| Beta | undefined |
About CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 23, 2021
Employees 158
Stock Exchange NASDAQ
Ticker Symbol CRBU
Website https://cariboubio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for CRBU stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 594.01% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Caribou Biosciences Inc. is scheduled to release its earnings on Mar 10, 2025,
during market hours.
Analysts project revenue of $1.84M, reflecting a -48.29% YoY shrinking and earnings per share of -0.42, making a 7.69% increase YoY.
Analysts project revenue of $1.84M, reflecting a -48.29% YoY shrinking and earnings per share of -0.42, making a 7.69% increase YoY.
7 months ago ·
Source
-25.35%
Caribou Biosciences shares are trading lower after...
Unlock content with
Pro Subscription
10 months ago ·
Source
-30.47%
Caribou Biosciences shares are trading lower after the company reported worse-than-expected Q4 financial results.
